Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sucampo Pharmaceuticals SCMP

Healthcare Drug Manufacturers - Specialty & Generic
"Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development... see more

Recent & Breaking News (NDAQ:SCMP)

Sucampo Announces Resolution of Par Pharmaceutical's ANDA for RESCULA(R)

GlobeNewswire February 11, 2015

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2015 Leerink Global Healthcare Conference

GlobeNewswire February 5, 2015

Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO

GlobeNewswire January 30, 2015

AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries

GlobeNewswire January 30, 2015

Robert J. Spiegel, M.D., FACP Joins Sucampo's Board of Directors

GlobeNewswire January 21, 2015

Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada

GlobeNewswire December 30, 2014

Sucampo Appoints John H. Johnson to Board of Directors

GlobeNewswire December 15, 2014

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 26th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 25, 2014

Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's

GlobeNewswire November 12, 2014

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Stifel 2014 Healthcare Conference

GlobeNewswire November 11, 2014

Sucampo Announces Third Quarter 2014 Financial Results

GlobeNewswire November 6, 2014

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Credit Suisse Global Healthcare Conference

GlobeNewswire November 5, 2014

Sucampo Pharmaceuticals, Inc. Announces Third Quarter 2014 Earnings Call

GlobeNewswire October 24, 2014

Sucampo Solidifies Leadership Team With Additions of CSO and Heads of Business Development, Regulatory Affairs

GlobeNewswire October 23, 2014

Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)

GlobeNewswire October 21, 2014

Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda

GlobeNewswire October 14, 2014

Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting

GlobeNewswire October 13, 2014

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA

GlobeNewswire October 9, 2014

Sucampo Announces Departure of Chief Financial Officer

GlobeNewswire October 6, 2014

Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation

GlobeNewswire September 29, 2014